Recent news on Tizanidine Hydrochloride

Acorda Therapeutics to Present at Friedman, Billings, Ramsey & Co ...  -  May 24, 2007
PharmaLive.com (press release),The Company's marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

FDA MedWatch: Zanaflex (tizanidine hydrochloride) Tablets and ...  -  Apr 12, 2007
PharmaLive.com (press release),The letter will he sent to physicians who have prescribed iizanidine hydrochloride, and pharmacists who have ordered tizanidine hydrochloride,

Acorda Therapeutics to Host Analyst and Investor Reception  -  Apr 25, 2007
Business Wire (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Acorda Therapeutics to Present at 7th Annual Fortis Biotech Conference  -  Apr 18, 2007
Genetic Engineering News (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data ...  -  Mar 19, 2007
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Acorda Therapeutics Reports Fourth Quarter and Full Year 2006 ...  -  Feb 20, 2007
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Acorda Therapeutics Announces Completion of Zanaflex Capsules ...  -  Jan 8, 2007
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity.

Acorda Therapeutics Elects Barry Greene, COO of Alnylam, to its ...  -  Jan 8, 2007
Business Wire (press release),The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Acorda Therapeutics to Receive Up to $10 Million from Paul Capital ...  -  Nov 29, 2006
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Acorda Therapeutics Reports Third Quarter 2006 Financial Results  Nov 2, 2006
For the quarter ended September 30, 2006, gross sales of Zanaflex Capsules(TM) (tizanidine hydrochloride) were $5.0 million and gross sales of Zanaflex(R ... -Genetic Engineering News (press release), Rodman & Renshaw Healthcare Conference 2006 Presenter Profiles  Nov 3, 2006
Acorda’s marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride) and Zanaflex® (tizanidine hydrochloride) tablets. ... -Business Wire (press release), Acorda Therapeutics Announces Expansion of Zanaflex Capsules(TM) ...  Oct 17, 2006
...high-volume prescribers. The Acorda sales team promotes Zanaflex Capsules(TM) (tizanidine hydrochloride). "This second expansion ... -Genetic Engineering News (press release), Acorda Therapeutics to Host Conference Call to Report Third ...  Oct 26, 2006
The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... -Business Wire (press release), Acorda Therapeutics to Present at the BioCentury Newsmakers in the ...  Aug 31, 2006
The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... -Business Wire

Acorda Therapeutics Provides Update on Clinical Development of ...  -  Dec 8, 2006
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Acorda Therapeutics Reports Second Quarter 2006 Financial Results  Aug 3, 2006
For the quarter ended June 30, 2006, gross sales were $3.9 million for Zanaflex Capsules(TM) (tizanidine hydrochloride) and $4.0 million for Zanaflex(R ... -Genetic Engineering News

Acorda Therapeutics Announces Directors Stepping Down  Aug 7, 2006
The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... -Genetic Engineering News

Acorda Therapeutics to Host Analyst and Investor Day  Jul 6, 2006
The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... -Genetic Engineering News



Acorda Therapeutics Reports First Quarter 2006 Financial Results  May 5, 2006
For the quarter ended March 31, 2006, gross sales of Zanaflex Capsules(TM) (tizanidine hydrochloride) were $2.3 million and gross sales of Zanaflex(R) tablets ... - Genetic Engineering News

Acorda Therapeutics to Present at Two Upcoming Conferences  May 8, 2006
The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... - Genetic Engineering News

Acorda Therapeutics Reports First Quarter 2006 Financial Results  May 5, 2006
For the quarter ended March 31, 2006, gross sales of ZanaflexCapsules(TM) (tizanidine hydrochloride) were $2.3 million and grosssales of Zanaflex(R) tablets ... - Finanzen.net





Acorda Therapeutics, Inc. [ACOR] President & CEO to Ring The ...  Apr 6, 2006
The Company's marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... - Market Wire

Acorda Therapeutics Reports Fourth Quarter and Full Year 2005 ...  Mar 31, 2006
The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... - Genetic Engineering News



Paul Royalty Fund Purchases Revenue Interest in Acorda's Zanaflex ...  Jan 19, 2006
Both products contain tizanidine hydrochloride, or tizanidine, one of the two leading treatments currently used for the management of spasticity. ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional